Share Price | Portage Biotech, Inc. Stock Analysis & Recommendation

Q: What does Portage Biotech, Inc. do?

Overview:Portage Biotech, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot:Most recent Net Profit: -1 Million (Quarterly Results - Sep 2024) Market cap: USD 6.43 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.24 Return on Equity: -386.34% Price to Book: 4.60 Contact Details:Registrar Address: Not available.

Q: Is Portage Biotech, Inc. technically bullish or bearish?

As of 27 August 2025, the technical trend for Portage Biotech, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by a daily moving average that indicates a positive short-term outlook, despite mixed signals from the MACD and Bollinger Bands across different time frames. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish. The overall performance shows a stark contrast in returns; the stock has gained 15.14% over the past week compared to a modest 1.05% gain in the S&P 500, but it has underperformed significantly over longer periods, with a 1-year return of -36.63% versus the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

71.14 k

Shareholding (Sep 2025)

FII

0.15%

Held by 13 FIIs

DII

99.81%

Held by 0 DIIs

Promoter

0.00%

How big is Portage Biotech, Inc.?

22-Jun-2025

As of Jun 18, Portage Biotech, Inc. has a market capitalization of 6.43 million and reported net sales of 0.00 million, with a net profit of -67.31 million over the last four quarters. The balance sheet shows shareholder's funds of 4.02 million and total assets of 7.78 million.

View full answer

What does Portage Biotech, Inc. do?

22-Jun-2025

Portage Biotech, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $1 million and a market cap of $6.43 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -386.34%.

View full answer

Is Portage Biotech, Inc. technically bullish or bearish?

20-Sep-2025

As of August 27, 2025, Portage Biotech, Inc. has a mildly bullish trend, supported by a positive daily moving average, although mixed signals from MACD and Bollinger Bands indicate varying performance, with a recent 15.14% gain contrasting a -36.63% return over the past year compared to the S&P 500's 17.14%.

View full answer

Compare Portage Biotech, Inc. with Similar Stocks

Passage Bio, Inc.LAVA Therapeutics NV Precision BioSciences, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 11 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.02

Return on Equity

-123.39%

Price to Book

1.16

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-10 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-87.68%

6 Months

-87.27%

1 Year

-91.3%

2 Years

-99.36%

3 Years

-99.78%

4 Years

-99.92%

5 Years

-99.79%

Portage Biotech, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-151.03%

EBIT to Interest (avg)

-9.55

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.24

Sales to Capital Employed (avg)

Tax Ratio

2.66%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

9.22%

ROCE (avg)

ROE (avg)

267.52%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.74

EV to EBIT

-0.65

EV to EBITDA

-0.66

EV to Capital Employed

-7.69

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-386.34%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.04%)

Foreign Institutions

Held by 13 Foreign Institutions (0.15%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -642.86% vs 73.08% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.50",
          "val2": "-1.60",
          "chgp": "-181.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.90",
          "val2": "0.20",
          "chgp": "-3,050.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.40",
          "val2": "-1.40",
          "chgp": "-642.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 90.98% vs 27.98% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.40",
          "val2": "-18.20",
          "chgp": "59.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.60",
          "val2": "-64.50",
          "chgp": "100.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.80",
          "val2": "-75.40",
          "chgp": "90.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.50

-1.60

-181.25%

Interest

0.00

Exceptional Items

-5.90

0.20

-3,050.00%

Consolidate Net Profit

-10.40

-1.40

-642.86%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -642.86% vs 73.08% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-7.40

-18.20

59.34%

Interest

0.00

Exceptional Items

0.60

-64.50

100.93%

Consolidate Net Profit

-6.80

-75.40

90.98%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 90.98% vs 27.98% in Mar 2024

All Annual Results

Company CV

About Portage Biotech, Inc.

Portage Biotech, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Portage Biotech, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Portage Biotech, Inc.?

Watch in Real-Time

What does Portage Biotech, Inc. do?

Is Portage Biotech, Inc. technically bullish or bearish?

Compare Portage Biotech, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Mar'25

About Portage Biotech, Inc.

Company Coordinates